Dr. Al-Kali on FDA Approval of Enasidenib in AML

August 1, 2017

Aref Al-Kali, MD

In Partnership With:

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).